Literature DB >> 25111982

Coronary artery disease and 10-year outcome after hospital admission for heart failure with preserved and with reduced ejection fraction.

Dan Rusinaru1, David Houpe, Catherine Szymanski, Franck Lévy, Sylvestre Maréchaux, Christophe Tribouilloy.   

Abstract

AIMS: The prognostic impact of coronary artery disease (CAD) in heart failure is debated. Whereas causes of death have been well described in patients with cardiomyopathy, little is known about how CAD influences causes of death in heart failure with preserved ejection fraction (HFPEF). We undertook a 10-year study and analysed causes of death in relation with CAD in HFPEF and in heart failure with reduced ejection fraction (HFREF). METHODS AND
RESULTS: Our prospective analysis included 591 consecutive patients (320 HFPEF and 271 HFREF) hospitalized for the first time for heart failure during 2000 and followed for 10 years. History of CAD was documented in 25% of HFPEF and 39% of HFREF patients (P < 0.001). Overall, CAD was independently predictive of all-cause and cardiovascular death. CAD had powerful prognostic impact in HFREF [adjusted hazard ratio (HR) 1.60 (1.19-2.15) for all-cause death, and adjusted HR 2.01 (1.38-2.92) for cardiovascular death]. In HFPEF, the association between CAD and cardiovascular death was no longer observed after adjustment [adjusted HR 1.01 (0.69-1.50)]. In HFREF, CAD was associated with increased risk of heart failure-related (adjusted HR 2.03 (1.21-3.43)] and myocardial infarction-related fatal events [adjusted HR 3.84 (1.16-12.7)], while HFPEF patients with CAD appeared at greater risk of sudden death [adjusted HR 2.22 (1.05-4.95)].
CONCLUSION: The prognostic impact of CAD is different in HFPEF compared with HFREF. Patients with HFPEF and CAD are at high risk of cardiovascular death, especially sudden death.
© 2014 The Authors. European Journal of Heart Failure © 2014 European Society of Cardiology.

Entities:  

Keywords:  Causes of Death; Coronary Artery Disease; Heart Failure; Prognosis

Mesh:

Year:  2014        PMID: 25111982     DOI: 10.1002/ejhf.142

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  22 in total

Review 1.  Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap.

Authors:  Sanjiv J Shah; Dalane W Kitzman; Barry A Borlaug; Loek van Heerebeek; Michael R Zile; David A Kass; Walter J Paulus
Journal:  Circulation       Date:  2016-07-05       Impact factor: 29.690

Review 2.  Management of Heart Failure with Preserved Ejection Fraction: Current Challenges and Future Directions.

Authors:  Bharathi Upadhya; Dalane W Kitzman
Journal:  Am J Cardiovasc Drugs       Date:  2017-08       Impact factor: 3.571

Review 3.  Evolution of a Geriatric Syndrome: Pathophysiology and Treatment of Heart Failure with Preserved Ejection Fraction.

Authors:  Bharathi Upadhya; Barbara Pisani; Dalane W Kitzman
Journal:  J Am Geriatr Soc       Date:  2017-11       Impact factor: 5.562

Review 4.  Therapy for heart failure with preserved ejection fraction: current status, unique challenges, and future directions.

Authors:  Bharathi Upadhya; Mark J Haykowsky; Dalane W Kitzman
Journal:  Heart Fail Rev       Date:  2018-09       Impact factor: 4.214

Review 5.  Heart Failure with Preserved Ejection Fraction in Older Adults.

Authors:  Bharathi Upadhya; Dalane W Kitzman
Journal:  Heart Fail Clin       Date:  2017-05-06       Impact factor: 3.179

6.  Outcomes of Individuals With and Without Heart Failure Presenting With Acute Coronary Syndrome.

Authors:  Stephen A Clarkson; Brittain Heindl; Anping Cai; Mark Beasley; Chrisly Dillon; Nita Limdi; Todd M Brown
Journal:  Am J Cardiol       Date:  2021-03-03       Impact factor: 3.133

Review 7.  Burden and Prevention of Adverse Cardiac Events in Patients with Concomitant Chronic Heart Failure and Coronary Artery Disease: A Literature Review.

Authors:  Louis Lavoie; Hanane Khoury; Sharon Welner; Jean-Baptiste Briere
Journal:  Cardiovasc Ther       Date:  2016-06       Impact factor: 3.023

8.  Metabolomic Profiling Identifies Novel Circulating Biomarkers of Mitochondrial Dysfunction Differentially Elevated in Heart Failure With Preserved Versus Reduced Ejection Fraction: Evidence for Shared Metabolic Impairments in Clinical Heart Failure.

Authors:  Wynn G Hunter; Jacob P Kelly; Robert W McGarrah; Michel G Khouri; Damian Craig; Carol Haynes; Olga Ilkayeva; Robert D Stevens; James R Bain; Michael J Muehlbauer; Christopher B Newgard; G Michael Felker; Adrian F Hernandez; Eric J Velazquez; William E Kraus; Svati H Shah
Journal:  J Am Heart Assoc       Date:  2016-07-29       Impact factor: 5.501

9.  Serum PINP, PIIINP, galectin-3, and ST2 as surrogates of myocardial fibrosis and echocardiographic left venticular diastolic filling properties.

Authors:  E Samuli Lepojärvi; Olli-Pekka Piira; Eija Pääkkö; Eveliina Lammentausta; Juha Risteli; Johanna A Miettinen; Juha S Perkiömäki; Heikki V Huikuri; M Juhani Junttila
Journal:  Front Physiol       Date:  2015-07-13       Impact factor: 4.566

Review 10.  Clinical Phenotypes in Heart Failure With Preserved Ejection Fraction.

Authors:  Rohan Samson; Abhishek Jaiswal; Pierre V Ennezat; Mark Cassidy; Thierry H Le Jemtel
Journal:  J Am Heart Assoc       Date:  2016-01-25       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.